Please assess the completion status of the following clinical trial:

Trial Title: Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have had histologically confirmed diagnosis of AML, in 1st complete remission, by a pathologic review at the H. Lee Moffitt Cancer Center and Research Institute. Any induction/consolidation regimen is permitted.~* General Inclusion Criteria:~  1. Age 56-74~ 2. Able to give informed consent~ 3. Hepatic and renal function: normal bilirubin, AST and ALT less than or equal to 2x normal limits, serum creatinine less than or equal to 1.5x normal~ 4. Left ventricular ejection fraction (LVEF) must be in normal range~ 5. FEV1 AND DLCO greater than or equal to 50% predicted (at planned time of transplantation)~ 6. ECOG PS less than or equal to 2 (at planned time of transplantation)~* Disease Specific Inclusion Criteria:~  1. Adverse-risk karyotype (del 5/5q, 7/7q, 3q, greater than or equal to 3 abnormalities):~ 2. Intermediate-risk karyotype \[46 XY, +8, -Y, +6, or any other isolated (\<3 total) non-random abnormality not included in the adverse-risk category or favorable-risk category below\]~* AML arising from antecedent hematologic disorder (e.g. MDS)~* Secondary AML (t-AML)~Exclusion Criteria:~* Acute Promyelocytic Leukemia(FAB M3) subtype~* Presence of (8;21) translocation or inversion 16/t(16;16) cytogenetic phenotype (i.e. favorable-risk AML)~* Eligible for and willing to undergo matched-sibling allogeneic transplantation~* Greater than 2 induction regimens required to achieve complete remission~* Duration of \> 8 weeks between completion of induction chemotherapy and initiation of consolidation chemotherapy~* No prior malignancy is allowed, except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 5 years.~* Prior extensive radiation therapy (\>25% of bone marrow reserve)~* Concomitant radiation therapy, chemotherapy, or immunotherapy~* Intrinsic impaired organ function (as stated above)~* Active infection~* Positive serum pregnancy test in women who have not yet reached menopause (no menstrual periods for \>12 months or who have not undergone tubal ligation or complete hysterectomy.~* Women who are breast-feeding~* Positive HIV testing~* Presence of CNS leukemia~* Uncontrolled insulin-dependent diabetes mellitus or uncompensated major thyroid or adrenal gland dysfunction~* Physical or psychiatric conditions that in the estimation of the PI or his designee place the patient at high-risk of toxicity or non-compliance

- Gender: ALL
- Minimum Age: 56 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Autologous Hematopoietic Progenitor Cell Transplantation (Type: OTHER): G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues